Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pemetrexed and cisplatin
Drug: pazopanib and pemetrexed

First Posted Date: 2009-03-30

Last Posted Date: 2013-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 107

Registration Number: NCT00871403

Locations: 🇬🇧
GSK Investigational Site, Sutton, Surrey, United Kingdom

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pazopanib
Drug: paclitaxel

First Posted Date: 2009-03-20

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00866528

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Placebo
Drug: Pazopanib

First Posted Date: 2009-03-20

Last Posted Date: 2021-02-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 940

Registration Number: NCT00866697

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2009-03-16

Last Posted Date: 2018-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT00861913

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

VEG111485: A QTc Study of Pazopanib

Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Other: Placebo for pazopanib
Drug: Pazopanib
Drug: Moxifloxacin
Other: Placebo for moxifloxacin

First Posted Date: 2009-03-13

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2

Registration Number: NCT00861029

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: doxorubicin + cyclophosphamide
Drug: paclitaxel + pazopanib
Procedure: surgery
Drug: pazopanib monotherapy

First Posted Date: 2009-02-23

Last Posted Date: 2014-03-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 101

Registration Number: NCT00849472

Locations: 🇨🇦
GSK Investigational Site, Quebec, Canada

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Phase 2

Completed

Conditions: Lymphedema

Interventions: Drug: Pazopanib

First Posted Date: 2009-01-22

Last Posted Date: 2023-10-16

Lead Sponsor: Kathy Miller

Target Recruit Count: 10

Registration Number: NCT00827372

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Phase 1

Completed

Conditions: Gynecologic Tumors

Interventions: Drug: Oral Topotecan
Drug: Pazopanib

First Posted Date: 2008-12-02

Last Posted Date: 2017-03-28

Lead Sponsor: Vector Oncology

Target Recruit Count: 33

Registration Number: NCT00800345

Locations: 🇺🇸
The West Clinic, Memphis, Tennessee, United States

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-11-11

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00788580

Adjuvant Pazopanib in Stage I NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Placebo
Drug: PAZOPANIB

First Posted Date: 2008-10-20

Last Posted Date: 2019-09-24

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 142

Registration Number: NCT00775307

Locations: 🇫🇷
Mont de Marsan - CH, Mont de Marsan, France
🇫🇷
Marseille - Hôpital Sainte Marguerite, Marseille, France
🇫🇷
Strasbourg - NHC, Strasbourg, France

and more 37 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy